Viewing data from:

LEQSELVI

NDA

DEURUXOLITINIB PHOSPHATE | N217900 | SUN PHARMACEUTICAL INDUSTRIES INC

1 strength6 unique patents1 unique exclusivity

Patent Timeline

6 unique patents, 1 exclusivity by expiration date

Active (6)TodayExclusivityIPRPTAB Challenge

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

2042

2043

2044

2045

Today

May. 4, 2037PGR

May. 21, 2041

May. 4, 2037

May. 10, 2044

Aug. 11, 2042

Oct. 10, 2044

NCE

Jul. 25, 2029

PTAB Proceedings

1 challenge on OB patents at the Patent Trial and Appeal Board

Trial #	Patent	Type	Petitioner	Status	Filed	Decision
PGR2021-00006	10561659	PGR	Incyte Corporation	Final Written Decision	2020-10-28	2025-06-17

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Aug 6, 2024	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 8MG BASE

RLD

6 patents1 exclusivity▴

TABLET;ORAL | Approved: Jul 25, 2024

Patents (6)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
10561659	May 4, 2037	—	—	—		—
11919907	May 21, 2041	—	—	Yes		—
12076323	May 4, 2037	—	—	—		—
12247034	May 10, 2044	—	Yes	Yes	—	—
12285432	Aug 11, 2042	—	—	—		—
12364699	Oct 10, 2044	—	—	—		—

Exclusivities (1)

Code	Date	Status
NCE	Jul 25, 2029	Active